Cardio Diagnostics Holdings is trading 10.55% up at $2.20 after filing an investor presentation emphasizing its commercialization strategy, AI-powered cardiovascular tests, and an $854 CMS reimbursement rate.
- The company will host an investor call on August 20, 2026, covering commercially available tests, reimbursement progress, clinical studies, and strategic growth initiatives.
- The broader healthcare sector is supporting sentiment, but the investor materials are the clearest company-specific catalyst.